Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Oncology /
      5. Prostate cancer

      Prostate cancer

      Prostate cancer is the most common cancer in men across Europe.[1] In 2022, across Europe, approximately 473,000 men were diagnosed with prostate cancer, and over 115,000 died as a result of the disease in the same timeframe.[1][2] There is a clear need for diagnostic and/or prognostic tools that facilitate personalised prostate cancer treatment and allow patients to access more targeted therapies, so that one day a prostate cancer diagnosis will be less frightening for patients to hear, and less distressing for healthcare professionals to say and act upon.[3][4][5]

      We are leaders in prostate cancer, and are dedicated to helping delay disease progression. We are working to get in front of cancer by harnessing the power of precision medicine, developing the next wave of therapeutics with highly selective targets and multiple platforms addressing heterogeneity and resistance.[6][7][8][9][10]
      istock-995420532.jpg
      Our heritage in prostate cancer
      At Johnson & Johnson Oncology, we have a legacy of innovation in prostate cancer treatment. We’ve been actively engaged in prostate cancer care for more than a decade.

      From our first treatment approval in 2011, we have continued to build on the insights from our clinical research and are committed to advancing a robust pipeline using differentiated scientific and innovative approaches, with the ambition to change and save lives.[11]
      JJ_Photo_Micro Onc PC-3 human prostate cancer cells_Shutterstock_425734612_1Star.jpg
      Our goal
      Building on this heritage, we are striving to ensure we can bring the right treatment, to the right patient, at the right time across the entire prostate cancer journey.

      Through a deep understanding of disease biology and a patient-focused approach, we propel transformative oncology science. Our team of dedicated scientists and professionals, together with collaborators, are exploring innovative approaches such as using novel intermediate endpoints, which could transform the entire trajectory of cancer and get us one step closer to a cure.[12][13]
      Grandfather and grandson taking a break in mountains, giving high five and eating sandwiches
      Our dedication to improving quality of life
      While extending life remains a key focus, patient quality of life is always at the forefront of our minds. With unwavering determination, we listen and learn with compassion to understand the needs of patients, caregivers, researchers, advocates and healthcare professionals who motivate us to define a new way forward. For us, helping to give patients more valuable time with their loved ones, to enjoy more of life’s meaningful moments, is what makes our work truly worthwhile.
      More from oncology at Johnson & Johnson Innovative Medicine EMEA

      References

      [1] Globocan 2022. International Agency for Research on Cancer. Cancer Today online analysis table – prostate cancer incidence in 2022, males, in Europe. Available at: https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&sexes=1&group_populations=1&multiple_populations=1&populations=908&types=0. Accessed: April 2025.
      [2] Globocan 2022. International Agency for Research on Cancer. Cancer Today online analysis table – prostate cancer mortality in 2022, males, in Europe. Available at: https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&sexes=1&group_populations=1&multiple_populations=1&populations=908&types=1. Accessed: April 2025.
      [3] Smith-Palmer et al. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urology. 2019 19, 19.
      [4] Roche, News, February 09, 2023. Roche Expands Collaboration with Janssen to Advance Personalised Healthcare Through Campaign Diagnostics. Available at: https://www.prnewswire.com/news-releases/roche-expands-collaboration-with-janssen-to-advance-personalised-healthcare-through-companion-diagnostics-301742757.html. Accessed: April 2025.
      [5] Maggie Benoit, June, 20, 2023. Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology. Available at: https://www.businesswire.com/news/home/20230620738981/en/Diatech-Pharmacogenetics-Announces-New-Collaboration-to-Advance-Precision-Testing-in-Oncology. Accessed: April 2025.
      [6] European Federation of Pharmaceutical Industries and Associations. About Medicines: Precision Medicine. Available at: https://www.efpia.eu/about-medicines/development-of-medicines/precision-medicine/#/. Accessed: April 2025.
      [7] ZYTIGA. Summary of Product Characteristics (October 2024). Janssen. Available at: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf. Accessed: April 2025.
      [8] AKEEGA. Summary of Product Characteristics (August 2024). Janssen. Available at: https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Accessed: April 2025.
      [9] ClinicalTrials.gov. A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer. NCT05441501. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05441501. Accessed: April 2025.
      [10] ClinicalTrials.gov. A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. NCT04644770. Available at: https://clinicaltrials.gov/study/NCT04644770. Accessed: April 2025.
      [11] Investor Johnson & Johnson. Development Pipeline. Available at: https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx. Accessed: April 2025.
      [12] Hait WN, et al. Moving upstream in anticancer drug development. Nat Rev. 2018; 18: 159-160.
      [13] Delgado A, et al. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021; 11 (4): 1121-1131.

      CP-512005
      May 2025